Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and...
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England &...
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and...
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC...
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in...
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether...
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive...
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore...
Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads